April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intraocular Inflammation Following Aflibercept (Eylea) Injection
Author Affiliations & Notes
  • Howard F Fine
    NJ Retina, Rutgers University Medicine and Dentistry of NJ, New Brunswick, NJ
  • Daniel B Roth
    NJ Retina, Rutgers University Medicine and Dentistry of NJ, New Brunswick, NJ
  • Sumit P Shah
    NJ Retina, Rutgers University Medicine and Dentistry of NJ, New Brunswick, NJ
  • Tahia Haque
    NJ Retina, Rutgers University Medicine and Dentistry of NJ, New Brunswick, NJ
  • Harold M Wheatley
    NJ Retina, Rutgers University Medicine and Dentistry of NJ, New Brunswick, NJ
  • Footnotes
    Commercial Relationships Howard Fine, Allergan (C), Auris Surgical Robotics (P), Genentech (C), Regeneron (C); Daniel Roth, Bayer (C), Forsight labs (P), Ohr (E), Regeneron (C), Thrombogenics (C); Sumit Shah, None; Tahia Haque, None; Harold Wheatley, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3855. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Howard F Fine, Daniel B Roth, Sumit P Shah, Tahia Haque, Harold M Wheatley; Intraocular Inflammation Following Aflibercept (Eylea) Injection. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3855.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report the characteristics and frequency of intraocular inflammation following intravitreal aflibercept injection.

Methods: Retrospective case series of consecutive patients who received intravitreal aflibercept in a group retina practice from November 2011 through June 2013.

Results: There were 28 cases of intraocular inflammation following a total of 5905 aflibercept injections among 1660 patients. The mean baseline acuity was 20/57 which decreased to 20/179 at diagnosis (p<0.0001), but recovered to 20/59 at month 1, 20/57 at month 3, and 20/52 at month 6 (p=NS). Vitreous culture and injection of antibiotics was performed in 8 cases, all were culture negative; the remainder received only topical corticosteroids.

Conclusions: The frequency of inflammation following aflibercept was 0.47% per injection. Visual acuity and inflammation returned to baseline within 1 month in most cases with topical corticosteroids.

Keywords: 513 endophthalmitis • 557 inflammation • 462 clinical (human) or epidemiologic studies: outcomes/complications  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×